drugset / Trial / NCT01195779

Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

NCT01195779

Phase 2 Terminated 4 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2584786A in healthy children 6 to 35 months of age.

Timeline

Start
2010-09-30
Primary completion
2011-03-22
Completion
2011-03-22

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK2321138A Vaccine Intramuscular
Subject GSK2584786A Vaccine Intramuscular
Comparator Influenza Virus Vaccine Vaccine Intramuscular

Indications